Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Thoratec Corp (NASDAQ: THOR) acted responsibly on behalf of investors’ profitability in the planned $3.4 billion sale to St. Jude Medical Inc (NYSE: STJ). 

On July 22 2015, Thoratec Corp (NASDAQ: THOR) and St. Jude Medical Inc (NYSE: STJ) announced that they had entered into a merger agreement.  Under the terms of the merger agreement, St. Jude will offer Thoratec shareholders $63.50 per share in cash for all outstanding shares. 

Based in Pleasanton, CA, and founded in 1976, Thoratec Corp develops, manufactures, and markets proprietary medical devices used for mechanical circulatory support for the treatment of heart failure patients. The company’s primary product lines include ventricular assist devices, including HeartMate II, CentriMag, PediMag and PediVAS, among other products. 

The investigation focuses on whether NASDAQ: THOR investors received the highest price and whether the directors of Thoratec Corp acted in the best interest of Thoratec Corp company and its shareholders.   

If you purchased Thoratec Corp (NASDAQ: THOR) prior to July 22, 2015, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324. 

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185